Haleon, long-term profit growth and shares on the London market
Published on 06/28/2026 at 10:36 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-28, 08:36.
Haleon (GB00BMX86B70) is back in view after a company update on medium-term profit growth and a separate analyst call on the shares. MarketScreener reported the operating-profit target on 24 June, while JPMorgan kept a Sell rating on 24 June as well.
What the company said
MarketScreener said Haleon is forecasting high single-digit growth in operating profit over the medium term. That is the headline number from the company update published on 24 June, and it gives investors a fresh benchmark for the consumer-health group. MarketScreener’s report on the update
JPMorgan stays cautious
The analyst side is equally concrete. MarketScreener’s timeline for Haleon lists JPMorgan’s 24 June note with a confirmed Sell rating, and it also records Rothschild & Co Redburn’s 18 June move to Neutral. That keeps the debate centered on valuation and execution, not on a single trading session. MarketScreener’s analyst timeline
All news and analysis on Haleon shares
The update and the analyst notes frame the next investor check-in around Haleon’s growth path and rating trend.
Oral care and pain relief
Haleon’s consumer-health portfolio includes brands such as Sensodyne, Panadol and Advil, which sit across oral care, pain relief and other everyday health categories. That mix matters because it ties the medium-term profit target to established mass-market products rather than a single launch cycle.
London listing details
The Haleon shares (GB00BMX86B70) trade on the London market in sterling. Price, market cap and a live timestamp were not securely verifiable from the available search set.
Key data on Haleon shares
- Company: Haleon plc
- ISIN: GB00BMX86B70
- Sector / industry: Consumer staples - household and personal products
- Index membership: FTSE 100
Disclaimer: This article is for information only and does not constitute investment advice.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
